Tryptamine Therapeutics Ltd (ASX:TYP, OTC:TYPTF) continues its run of good clinical outcomes with encouraging interim results from the first four participants in its Phase 2a clinical trial assessing TRP-8802 – oral psilocybin – for Irritable Bowel Syndrome (IBS).
The study, conducted at Massachusetts General Hospital (MGH), is notable for being the first administration of psilocybin in a clinical setting at the hospital.
Its aim is to evaluate the safety and efficacy of TRP-8802 in treating IBS symptoms, particularly abdominal pain and gastro-intestinal anxiety, through its interaction with serotonin pathways within the ‘gut-brain axis’.
Improved patient outcomes
“These positive interim results from the first four patients within the Phase 2a Clinical Study at MGH provide another strong indication of the broad potential of Tryp’s clinically-backed product suite to achieve improved patient health outcomes,” CEO Jason Carroll said.
To date, four out of up to 10 participants have successfully received treatment and interim results indicate that 75% have reported a clinically meaningful reduction in abdominal pain and associated anxiety.
Positive trends were also observed in patients with pre-existing anxiety and depression, suggesting potential broader mental health benefits.
Multiple advantages
These interim findings reinforce the viability of IBS as a target condition for TRP-8803, Tryp’s lead asset, an innovative intravenous (IV) psilocin-based formulation.
TRP-8803 offers multiple advantages over oral psilocybin, including faster onset under 20 minutes, precise control of treatment duration and scalability for commercial use.
The IBS trial forms part of Tryp’s broader clinical development program, which has included successful Phase 2a studies in Binge Eating Disorder (BED) and Fibromyalgia.
Results from these earlier studies demonstrated significant reductions in binge eating episodes and meaningful pain relief.
The Phase 2a IBS trial is on track for completion in the first half of 2025.
Data from the study will be incorporated into Tryp’s expanding proprietary datasets to inform future clinical development pathways for TRP-8803.
Substantial commercial potential
With IBS impacting 20% of Australians and 15% of the US population, the company sees substantial commercial potential for TRP-8803 to address this debilitating condition and improve patient quality of life.
“In the first instance, it was exciting to see the interim results reporting a clinically meaningful decrease in abdominal pain and anxiety stemming from IBS symptoms,” Carroll continued.
“Looking ahead, this interim analysis highlights that IBS is highly likely to be a viable indication for Tryp to pursue for commercialisation with TRP-8803 (IV-infused psilocin).
“While the MGH team will dose the remaining IBS patients, our work will commence to incorporate these interim results into our expanding proprietary dataset. This will, in turn, underpin the company’s future clinical trial pipeline.
“Tryp’s pipeline will be solely focused on TRP-8803, given the significant competitive advantage we see with TRP-8803 when compared to oral psilocybin.
“We look forward to providing additional details from the Phase 2a IBS trial for TRP-8802 as they are received, along with the forthcoming initiation of Phase 2 trials for Tryp’s TRP-8803 IV-infused psilocin therapy.”